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OBJECTIVES: To evaluate the budget impact of guideline adher-
ent acute coronary syndrome (ACS) therapy over 12 months
from the perspective of statutory sick funds in Germany.
METHODS: Most current clinical guidelines recommend clopi-
dogrel (in addition to ASS), beta blockers, ace-inhibitors and
statins for at least 12 months after ACS. We evaluated the poten-
tial 1 year budget impact of improving the medication pattern in
ACS towards an optimal drug usage as deﬁned by the guidelines.
Clopidogrel effect estimates were from the CURE and CLARITY
study, effect estimators for the other recommended drugs were
obtained from meta-analyses. Due to uncertainty regarding the
additive effects three scenarios were calculated: 1) “minimum”
effect (2 out of 4 drugs add additively), 2) “mean” (3 out of 4
drug effects) and 3) “maximum” (all 4 drug effects are addi-
tively). Costs were modelled using recent drug prices and pub-
lished German event costs. RESULTS: For 350,000 ACS patients
(including 40% ST-elevation myocardial infarction) compared to
a drug utilization pattern as in CURE 15,676 to 20,793 events
(Scenario 1 to 3) could be avoided. This assumes an optimal
achievable guideline adherence rate of 95% for clopidogrel and
statins, 90% for ACE-inhibitors and 85% beta blockers. The
corresponding additional costs for improved guideline adherent
therapy are between +3.2% and -1.9% compared to baseline.
Costs per event avoided are between 1882€ and -824€. Mean
costs per patient increase by 84€ to -49€ given yearly mean
calculatory costs of 2636€. Besides the uncertainty accounted for
by the scenarios uni- and multivariate sensitivity analysis showed
stable results. CONCLUSIONS: In clinical practice an improved
adherence of physicians to post ACS medication guidelines
would result in a minor increase or even decrease of budget for
the German sick funds. Furthermore, a signiﬁcant reduction of
major cardiovascular events after ACS could be achieved.
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OBJECTIVES: Thrombolysis for stroke has shown to be cost-
effective despite its pharmaceutical high cost because the evolu-
tion of survivors to disability is reduced in a 30%. Given its size,
more than 100,000 by year, it is worthwhile an economic
approach to understand the impact of its introduction at a popu-
lation level in terms of budget of the Spanish health system and
health gain. The objective of this study is to calculate the budget
impact analysis of thrombolysis in Spain by means of a discrete
event simulation model. METHODS: The budget impact
analysis was based on the estimation of incidence of stroke and
the prevalence of stroke-related disability in Spain from 2000 to
2015 and hospital and social costs. A discrete event simulation
model was built to represent the ﬂow of stroke patients in Spain
from incidence to disability and death with and without throm-
bolysis. RESULTS: The prevalence of dependent patients would
decrease from 150,236 to 146,172 if a 10% of stroke patients
received thrombolytic treatment from 2000 to 2015. The ﬁrst 5
years the cost of intervention surpasses the saved cost because of
less dependent patients. The saved costs move ahead in 2005 and
the gap with intervention costs grows till 2015. Beneﬁt in effec-
tiveness by year rises corresponds with a net gain of 156.6 in
2000 and 1360.2 QALYs in 2015. CONCLUSIONS: Throm-
bolysis impact onto the health and social budget entails a net
beneﬁt after ﬁve years and the gain in health grows continuously
in correlation with the avoided dependent patients. On the other
hand, the validation of the model enlightens the adequacy of the
discrete event simulation approach to represent the epidemiology
of stroke in order to calculate the budget impact analysis.
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OBJECTIVES: To estimate the impact of treating with statins
to low-density lipoprotein cholesterol (LDL-C) targets of
<3.0 mmol/L and <2.0 mmol/L in terms of number and cost of
cardiovascular (CV) events avoided over a ﬁve-year period for
regional health economies (RHEs) in the UK from an NHS
perspective. METHODS: Absolute risk reductions (ARR) in inci-
dence of myocardial infarction (MI), coronary revascularisation
and stroke based on treatment to alternative LDL-C targets were
taken from an analysis based on a meta-analysis of 14 ran-
domised controlled trials of statin therapy. The average popula-
tion size for each RHE was based on the average list size from
Quality and Outcomes Framework (QOF) April 2006-March
2007. The number of patients with CVD and/or diabetes in each
RHE was calculated using QOF prevalence adjusted to account
for patients on multiple registers. The % reduction in CV events
was applied to estimate the number of CV events avoided in each
RHE; costs of events avoided were calculated using the National
Tariff 2007–08. RESULTS: Treating to an LDL-C target of
<3.0 mmol/L resulted in the following CV events avoided (asso-
ciated cost savings): 1337 (£5.8million) for an average Primary
Care Trust (PCT) in England; 1526 (£6.6million) for an average
Health Board (HB) in Scotland; 639 (£2.8million) for an average
Local Health Board (LHB) in Wales: 1783 (£7.7million) for an
average Health and Social Services Board (HSSB) in Northern
Ireland. Treating to an LDL-C target of <2.0 mmol/L resulted in
the following CV events avoided (associated cost savings): 2004
(£8.7million), 2,289 (£9.9million), 961 (£4.2million) and 2674
(£11.5million) for an average PCT, HB, LHB and HSSB, respec-
tively. CONCLUSIONS: Based on this analysis, treating to an
LDL-C target of <2.0 mmol/L rather than <3.0 mmol/L results in
a substantial beneﬁt in terms of additional CV events avoided
and associated cost savings for each RHE within the UK.
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